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INTRODUCTION
Neuroleptic malignant syndrome (NMS) is an uncommon 
and potentially fatal untoward drug reaction associated with 
neuroleptic agents.1 It presents with panoply of clinical mani-
festations including fever, muscular rigidity, altered sensorium, 
leukocytosis, and elevated serum creatinine kinase. Signs of au-
tonomic instability such as tachycardia, hypertension, diapho-
resis, and tachypnea also can be present. Together with sup-
portive measures and the withdrawal of the offending agent, 
administration of the skeletal muscle relaxant, dantrolene, 
along with dopamine agonists, bromocriptine or amantadine, 
are necessary interventions in most cases. Although incidence 
is reported at only 0.02 to 3% in patients using neuroleptic 
medications,2 mortality rates approach 10% and are related to 
complications arising from acute renal failure, acute respiratory 
failure, cardiac injury, and sepsis.3 Therefore, preventions and 
identification of risk factors associated with NMS are crucial.
We present a patient with hypoxic-ischemic injury to the 
basal ganglia secondary to a provoked asthma attack who re-
ceived the atypical antipsychotic, quetiapine, in rehabilitation 
and subsequently developed neuroleptic malignant syndrome.
CASE REPORT
A 48-year-old male asthmatic developed a hypoxic re-
spiratory arrest. His past medical history was significant 
for severe asthma with frequent exacerbations. He had no 
neurologic history and was otherwise healthy. He was em-
ployed as a painter for a local vehicle resale company and 
endeavored to paint a project car at home without proper 
ventilation. Overcome by paint fumes, he developed a respi-
ratory arrest and emergency medical services were contacted. 
Upon their arrival, the patient was cyanotic and brady-
cardic. He entered asystole and treatment measures, in accor-
dance with Advanced Cardiovascular Life Support guidelines, 
were administered with return of spontaneous circulation 
approximately six minutes after arrest. The patient was intu-
bated and transferred to the intensive care unit (ICU). Upon 
extubation, he exhibited difficulties with speech, weakness 
in the right arm, cognitive and motor slowing, and agitation. 
Magnetic resonance imaging (MRI) of the brain displayed 
diffusion restriction in bilateral cortical areas and basal gan-
glia, consistent with hypoxic injury (Figure 1). Due to agita-
tion, he was placed on 50 milligrams of quetiapine and 50 
milligrams of trazodone at bedtime. He slowly improved 
and was transferred to an inpatient rehabilitation facility.
Figure 1. T2-MRI (left) and FLAIR MRI (right) taken within five days 
of the paitent’s cardiopulmonary arrest revealed high signals involv-
ing the putamen and caudate bilaterally, indicating ischemia. 
The patient was treated at the rehabilitation center for seven 
days, during which time quetiapine and trazodone were con-
tinued. Increased spasticity in his extremities developed and 
baclofen was added to his medication regimen, however, he 
experienced progressive tightness and rigidity of the extremi-
ties and decreased responsiveness. Tachypnea and a fever of 
38.1°C developed. He was transferred to the ICU at an acute 
care hospital for evaluation of a possible infectious cause, 
none of which was found via imaging or laboratory studies.
The patient remained tachypneic, rigid, feverish, and be-
came obtunded. Upon medication review, it was discovered 
that he was inadvertently given at least 100 milligrams of que-
tiapine and 50 milligrams of trazodone each evening at the re-
habilitation facility for an unknown length of time. Given this 
information and the clinical picture, neuroleptic malignant 
syndrome was suspected. A repeat MRI of the brain showed 
evolution of the hypoxic changes in the basal ganglia (Figure 
2). At this time, a neurology consultation was obtained and 
treatment with dantrolene and amantadine was initiated. The 
patient exhibited significant improvement within the first 
24 hours of treatment, especially with muscle rigidity. Fortu-
nately, there were no renal or cardiac complications from the 
event and most symptoms were resolved within one week. 
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continued.
His arousal and attention improved, but the hy-
poxic encephalopathy continued. On discharge, 
the patient returned to inpatient rehabilitation.
Figure 2. T2-MRI (left) and FLAIR MRI (right) taken approximately 
19 days after arrest, showing evolution ischemic damage in bilateral 
basal ganglia. 
DISCUSSION
Neurologic sequelae arising in survivors of cardiopul-
monary arrest are a significant cause of morbidity. In acute 
ischemic stroke, cerebral hypoperfusion generally is con-
fined to a focal vascular distribution, whereas in cardiac ar-
rest, the lack of cerebral blood flow is global in nature, leav-
ing the entire brain vulnerable to injury via both direct and 
reperfusion mechanisms. Areas especially prone to hypoxic 
injury include the cerebellum, hippocampi, cortex, and basal 
ganglia; all areas of high metabolic demand for oxygen and 
glucose.4,5 Basal ganglia involvement has been described in 
neuroleptic malignant syndrome,6,7 likely due to its dopami-
nergic neural circuitry involving the nigrostriatal pathways.2
Prior to receiving neuroleptics, our patient suffered from 
hypoxic-ischemic damage of the basal ganglia, particularly 
involving the putamen and caudate bilaterally, from a car-
diopulmonary arrest. The cause of NMS is suspected to be 
due to excessive dopaminergic blockade within the brain, 
explaining the risks associated with antipsychotic agents, 
which act as dopaminergic antagonists. First generation anti-
psychotics are implicated more commonly than second gen-
eration, or “atypical,” antipsychotics due to their higher af-
finity for dopamine receptors. However, both classes have 
been implicated in NMS. Additionally, high doses and rapid 
dose escalation of antipsychotic agents place patients at in-
creased vulnerability to NMS.8 Other factors also contribute 
to the development of NMS, such as preexisting central ner-
vous system disorders, dehydration, and malnutrition.9-12
The blockade of dopamine in already damaged nigros-
triatal dopaminergic circuits may have contributed to the 
emergence of NMS in this patient. To our knowledge, he 
had never been exposed to quetiapine in the past. During his 
hospitalization, he received a therapeutic dose of quetiap-
ine daily but began receiving double the dose in error at re-
habilitation before developing NMS. This error highlights 
the need for all medical facilities to have proper dosing pre-
cautions in place and effective medication administration.
CONCLUSION
We recommend that dopamine receptor antagonists should 
be used with caution or avoided in patients with hypoxic 
or ischemic injury to the basal ganglia, as the risk of further 
dopamine blockade could place the patient at risk for neu-
roleptic malignant syndrome. We also recommend early 
neurological consultation in patients with hypoxic-ischemic en-
cephalopathy, as this may direct therapy and improve outcomes.
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